/New Open Source: First Quarter Report of 2026

NEWS

New Open Source: First Quarter Report of 2026

Shenzhen Stock Exchange

2026/04/24

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Securities code: 300109 Securities abbreviation: New Kaiyuan Announcement number: 2026-025

Boai New Kaiyuan Medical Technology Group Co., Ltd.

2026 First Quarter Report

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

Important content reminder:

The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the first quarter financial accounting report has been audited

□Yes No

1. Main financial data

(1) Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

Increases and decreases in this reporting period compared with the same period last year This reporting period compared with the same period last year

(%)

Operating income (yuan) 342,044,807.76 324,863,000.55 5.29% of net profit attributable to shareholders of listed companies

64,750,179.59 80,420,300.50 -19.49% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses 63,022,035.68 69,416,240.04 -9.21% (yuan)

Net cash flow from operating activities

71,638,434.51 47,514,176.29 50.77% (yuan)

Basic earnings per share (yuan/share) 0.13 0.17 -23.53% Diluted earnings per share (yuan/share) 0.13 0.17 -23.53% Weighted average return on equity 1.74% 2.19% -0.45% Increase or decrease at the end of this reporting period compared with the end of the previous year The end of this reporting period The end of the previous year

(%)

Total assets (yuan) 4,329,773,376.64 4,368,292,558.77 -0.88% owned by shareholders of listed companies

3,700,595,037.81 3,684,725,319.55 0.43% interest (yuan)

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

(2) Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan Item Amount for this reporting period Description

Gains and losses on disposal of non-current assets (including accrued

292,059.63

Offset portion of asset impairment provision)

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

4,088,086.08

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Except for effective transactions related to the company’s normal business operations,

In addition to futures hedging business, non-financial enterprises hold financial

Changes in fair value of assets and financial liabilities -1,579,492.91

Profit and loss and disposal of financial assets and financial liabilities

profit and loss

Other non-operating income other than the above items and

-311,801.96

expenditure

Less: Income tax impact 623,339.87

Amount of impact on minority shareholders’ equity (after tax) 137,367.06

Total 1,728,143.91 --

Details of other profit and loss items that meet the definition of non-recurring profits and losses

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

(3) Changes in major accounting data and financial indicators and their reasons

Applicable □Not applicable

Unit: Yuan

Increase this year compared with last year

Item March 2026 December 2025 Difference Decrease % for explanation of reasons for changes

Mainly due to the company's prepayments in this period 49,585,801.08 29,600,974.14 19,984,826.94 67.51%

This is due to the increase in material costs compared with the previous period. Mainly due to the company’s new development expenditures in the current period 198,536.71 198,536.71 ----- Capitalizable R&D project expenditures

To. Mainly due to the increase in bill settlement business volume during the current period when the company adopted bills payable 99,954,994.00 22,849,438.22 77,105,555.78 337.45%

To.

Mainly due to the company's payment of accounts payable in this period 126,919,212.71 247,046,492.99 -120,127,280.28 -48.63%

Due to the increase in project costs.

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Employee salaries payable are mainly due to the company paying 10,527,879.77 in the current period 17,320,446.88 -6,792,567.11 -39.22%

Remuneration is due to annual performance pay.

Mainly due to the company's payment of taxes payable in this period 3,106,297.17 7,373,572.66 -4,267,275.49 -57.87%

Due to taxes due at the beginning of the year.

Due within one year Mainly due to non-current liabilities due within one year for repayment in this period 5,364,044.87 11,864,044.87 -6,500,000.00 -54.79% Financial institution borrowings due within one year

Debt caused.

Other negative currents are mainly due to the company's pending balance at the end of the period 2,139,096.08 1,534,376.67 604,719.41 39.41%

Debt due to increase in output tax.

Other comprehensive income Mainly due to the company’s foreign currency in the current period 651,948.47 250,570.33 401,378.14 160.19%

Profit due to changes in statement translation differences.

Item First quarter of 2026 First quarter of 2025 Difference Increase this year compared with the previous year

Reason for change minus %

Mainly due to the increase in the company's exchange financial expenses in this period 7,230,234.99 -6,573,826.89 13,804,061.88 -209.99% compared with the same period last year.

Mainly due to the receipt of government subsidies related to production and operation in the current period 4,091,002.19 2,242,083.43 1,848,918.76 82.46%

due to the increase in the same period last year. The change in fair value is mainly due to the company’s investment income (loss) in the current period. The fair value of Hong Kong Yongtai Biological Co., Ltd.

-1,579,492.91 10,038,006.02 -11,617,498.93 -115.74%

If it is not filled in with “-”, the income generated by the change in value will decrease.

column).

Credit impairment loss is mainly due to the decrease in the company's current losses in the current period (losses are listed as "-" -146,407.95 1,260,358.88 -1,406,766.83 111.62%) compared with the same period last year. Asset disposal income is mainly due to the company's non-current profits in the current period (losses are listed with "-" due to the increase in asset disposal income).

Mainly due to the decrease in non-operating income received by the company in the current period 35,817.37 1,178,963.53 -1,143,146.16 -96.96% government subsidies and fines.

Mainly due to the increase in the company's non-operating charitable donations and other expenses in the current period 434,948.21 37,395.28 397,552.93 1063.11%.

Item First quarter of 2026 First quarter of 2025 Difference Increase this year compared with the previous year

Explanation of reasons for changes

minus %

Current business activities

333,787,468.92 351,655,897.01 -17,868,428.09 -5.08%

Cash inflow subtotal

Current business activities

262,149,034.41 304,141,720.72 -41,992,686.31 -13.81%

Gold outflow subtotal

Products from operating activities Mainly due to the cash flow generated by the company's purchases in the current period 71,638,434.51 47,514,176.29 24,124,258.22 50.77% Cash paid for goods compared with the same period last year

The net amount decreased during the period.

Investment activities are now

17,274.18 290,000,000.00 -289,982,725.82 -99.99%

Cash inflow subtotal

Investment activities are now

91,525,996.50 89,193,480.17 2,332,516.33 2.62%

Gold outflow subtotal

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

investment activity assets

Mainly due to the cash flow generated from the company's deposit certificates in the previous period -91,508,722.32 200,806,519.83 -292,315,242.15 -145.57%

Due to the entry of mature funds into the account.

Net amount

Fundraising activities are now

5,000,000.00 245,160,000.00 -240,160,000.00 -97.96%

Cash inflow subtotal

Fundraising activities are now

57,443,802.74 206,497,499.56 -149,053,696.82 -72.18%

Gold outflow subtotal

financing activity assets

Mainly due to the cash flow generated by the company's repurchase in this period -52,443,802.74 38,662,500.44 -91,106,303.18 -235.65%

Due to the increase in cash expenses for shares.

Net amount

2. Shareholder information

(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

Unit: Share Total number of common shareholders at the end of the reporting period 19,380 Total number of preference shareholders whose voting rights were restored at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)

Shareholding ratio Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Number of shares held

(%) Number of shares of piece Share status Quantity

42,095,222.0 31,571,416.0 22,700,000.0 Wang Donghu Domestic natural person 8.71% Pledge

0 0 0

17,560,000.0

He Haibo Domestic natural person 3.63% 0.00 Not applicable 0

14,709,240.0

Yang Haijiang Domestic natural person 3.04% 0.00 Not applicable 0

13,992,452.0 11,000,000.0 Wang Jianqiang Domestic natural person 2.89% 0.00 Pledge

0 0Wuhu Great Wall Guolong

INVESTMENT MANAGEMENT LIMITED

Company - Wuhu Chang Others 2.01% 9,721,086.00 0.00 Not applicable 0Qian Investment Center

(limited partnership)

Pan Qingling Domestic natural person 1.87% 9,018,731.00 0.00 Not applicable 0 Hong Kong Securities Clearing Company

Overseas legal person 1.45% 7,024,942.00 0.00 Not applicable 0 Co., Ltd.

Dong Hanwen Domestic natural person 1.35% 6,521,100.00 0.00 Not applicable 0 Zhang Yufen Domestic natural person 1.32% 6,373,800.00 0.00 Not applicable 0 Zhao Tian Domestic natural person 1.04% 5,009,650.00 0.00 Not applicable 0Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing and shares locked by executives)

Share type

Name of shareholder Number of shares without selling restrictions held

Share Type Quantity

17,560,000.0 He Haibo 17,560,000.00 RMB ordinary shares

14,709,240.0 Yang Haijiang 14,709,240.00 RMB ordinary shares

13,992,452.0 Wang Jianqiang 13,992,452.00 RMB ordinary shares

10,523,806.0 Wang Donghu 10,523,806.00 RMB ordinary shares

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Wuhu Great Wall Guolong Investment Management Co., Ltd.

－Wuhu Changqian Investment Center (limited shares 9,721,086.00 RMB ordinary shares 9,721,086.00 units)

Pan Qingling 9,018,731.00 RMB ordinary shares 9,018,731.00 Hong Kong Securities Clearing Company Limited 7,024,942.00 RMB ordinary shares 7,024,942.00 Dong Hanwen 6,521,100.00 RMB ordinary shares 6,521,100.00 Zhang Yufen 6,373,800.00 RMB ordinary shares 6,373,800.00 Zhao Tian 5,009,650.00 RMB ordinary shares 5,009,650.00 Explanation on the related relationships or concerted actions of the above shareholders Wang Donghu and Yang Haijiang are the actual controllers and persons acting in concert of the company

Description of the top 10 shareholders participating in margin trading and securities lending business (such as

Not applicable

Yes)

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders

□Applicable Not applicable

(3) Changes in restricted shares

Applicable □Not applicable

Unit: Share

Restrictions on sales are lifted in this period. Restrictions on sales are added in this period. Name of shareholder on the date when restrictions on sales are to be lifted. Number of shares subject to restrictions on sales at the beginning of the period. Number of shares subject to restrictions on sales at the end of the period. Reasons for restrictions on sales.

Number of shares Number of shares Phase Zhang Junzheng 682,255.00 0 0 682,255.00 Executive locked shares ------Yang Hongbo 747,000.00 0 0 747,000.00 Executive locked shares ------

31,571,416.0 31,571,416.0

Wang Donghu 0 0 Executive lock stocks ------

0 0

Zhao Wei 24,955.00 0 0 24,955.00 Executive locked shares ------ Qu Yunxia 198,200.00 0 0 198,200.00 Executive locked shares ------ Yu Jiangtao 296,250.00 0 0 296,250.00 Executive locked shares ------ Yan Chongchao 279,756.00 0 93,252.00 373,008.00 Executive locked shares ------Chang Tao 11,250.00 0 3,750.00 15,000.00 Executive locked shares ------Mao Haizhan 481,288.00 0 0 481,288.00 Executive locked shares ------Zou Xiaowen 281,809.00 0 0 281,809.00 Executive locked shares ------Li Shegang 230,625.00 0 0 230,625.00 Executive locked shares ------Wang Shigang 195,075.00 0 0 195,075.00 Executive locked shares ------Liu Aimin 426,235.00 0 0 426,235.00 Executive locked shares ------Zhang Dedong 337,500.00 0 0 337,500.00 Executive locked shares ------Xing Xiaoliang 264,375.00 0 0 264,375.00 Executive locked shares ------

36,027,989.0 36,124,991.0

Total 0 97,002.00 -- --

0 0

3. Other important matters

Applicable □Not applicable

Completion of cancellation of repurchased shares and changes in shares: The company held the 21st meeting of the fifth session of the Board of Directors on January 7, 2026, and the

The second extraordinary general meeting of shareholders in 2026 reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions" item by item, and agreed that the company would use its own

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

There are funds to repurchase shares through centralized bidding transactions for cancellation and reduction of registered capital. A total of 2,669,400 shares were repurchased and canceled this time, accounting for 10% of the shares before repurchase and cancellation.

0.55% of the company's total share capital. After the repurchase and cancellation, the company's total share capital was reduced from 486,050,005 shares to 483,380,605 shares.

Serial number Summary of important matters Disclosure date Temporary report disclosure website query index

1 Completion of cancellation of repurchased shares and changes in shares March 30, 2026 Juchao Information Network (Announcement No.: 2026-023)

4. Quarterly Financial Statements

(1) Financial statements

Consolidated balance sheet

Prepared by: Boai New Kaiyuan Medical Technology Group Co., Ltd.

March 31, 2026

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 649,903,734.46 691,853,451.97 Settlement reserves

Loan funds

Trading financial assets 22,211,110.27 23,790,603.18 Derivative financial assets

Notes receivable 10,486,486.09 13,227,089.27 Accounts receivable 308,547,478.30 307,886,894.92 Receivables financing 87,648,588.16 85,354,640.94 Prepayments 49,585,801.08 29,600,974.14 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 17,498,445.86 19,431,553.47 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 294,797,763.32 318,312,074.52

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 34,322,877.63 39,637,587.17 Total current assets 1,475,002,285.17 1,529,094,869.58 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

long term equity investment

Other equity instrument investments 390,220,000.00 390,220,000.00 Other non-current financial assets 3,992,000.00 3,992,000.00 Investment real estate 79,529,591.27 80,065,730.84 Fixed assets 1,365,683,084.24 1,407,113,753.98 Construction in progress 447,498,182.09 402,320,298.16

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

productive biological assets

oil and gas assets

Right-of-use assets 2,347,451.37 2,636,191.38 Intangible assets 173,130,491.21 174,260,506.99

Among them: data resources

Development expenditure 198,536.71

Among them: data resources

Goodwill 256,354,643.47 256,354,643.47 Long-term deferred expenses 8,863,747.31 9,501,870.08 Deferred income tax assets 63,980,651.51 62,406,794.80 Other non-current assets 62,972,712.29 50,325,899.49 Total non-current assets 2,854,771,091.47 2,839,197,689.19 Total assets 4,329,773,376.64 4,368,292,558.77 Current liabilities:

Short-term borrowings 168,415,507.58 163,415,507.58 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable 99,954,994.00 22,849,438.22 Accounts payable 126,919,212.71 247,046,492.99 Advance receipts

Contract liabilities 20,718,418.06 20,873,446.07 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 10,527,879.77 17,320,446.88 Taxes payable 3,106,297.17 7,373,572.66 Other payables 22,653,761.73 26,865,091.84 Including: interest payable

Dividends payable 52,482.98 52,482.98 Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 5,364,044.87 11,864,044.87 Other current liabilities 2,139,096.08 1,534,376.67 Total current liabilities 459,799,211.97 519,142,417.78 Non-current liabilities:

insurance contract reserves

Long-term borrowings 153,904,943.15 154,000,000.00 Bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 1,206,340.76 1,296,373.95 Long-term payables 225,771.00 247,065.00 Long-term employee benefits payable

Estimated liabilities

Deferred income 39,779,878.42 35,044,165.94 Deferred income tax liabilities 3,322,559.97 3,431,461.18 Other non-current liabilities

Total non-current liabilities 198,439,493.30 194,019,066.07 Total liabilities 658,238,705.27 713,161,483.85 Owners’ equity:

Share capital 483,380,605.00 486,050,005.00

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 1,987,201,132.53 2,034,505,227.53 Less: treasury shares

Other comprehensive income 651,948.47 250,570.33 Special reserves 10,234,284.43 9,542,628.90 Surplus reserves 171,738,262.35 171,738,262.35 General risk reserves

Undistributed profits 1,047,388,805.03 982,638,625.44 Total owners’ equity attributable to the parent company 3,700,595,037.81 3,684,725,319.55 Minority shareholders’ equity -29,060,366.44 -29,594,244.63 Total owners’ equity 3,671,534,671.37 3,655,131,074.92 Total liabilities and owners’ equity 4,329,773,376.64 4,368,292,558.77 Legal representative: Zhang Junzheng Person in charge of accounting work: Liu Aimin Person in charge of the accounting department: Li Chunping

Consolidated income statement

Unit: Yuan

Item Amount for the current period Amount for the previous period

Total operating income 342,044,807.76 324,863,000.55 Including: operating income 342,044,807.76 324,863,000.55 Interest income

Premiums earned

Fee and commission income

Total operating costs 268,856,719.05 247,564,155.31 Including: operating costs 193,180,886.82 181,689,373.85 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 4,025,890.30 3,240,192.32 Sales expenses 12,580,333.12 11,390,142.04 Management expenses 34,539,832.59 36,285,040.04 Research and development expenses 17,299,541.23 21,533,233.95Financial expenses 7,230,234.99 -6,573,826.89Including: Interest expenses 2,193,904.11 2,005,061.81

Interest income 2,991,895.14 4,159,145.62 plus: other income 4,091,002.19 2,242,083.43

Investment income (losses are filled in with "-"

column)

Of which: for associates and joint ventures

corporate investment income

Measured at amortized cost

Income from derecognition of financial assets

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gain (loss calculated as

Fill in the column with "-" sign)

Gains from changes in fair value (losses calculated as

-1,579,492.91 10,038,006.02 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

-146,407.95 1,260,358.88 fill in the column)

Asset impairment losses (losses are marked with "-"

Fill in the column)

Asset disposal income (losses are marked with "-"

292,096.15 165.59 fill in the column)

3. Operating profit (loss is filled in with "-"

75,845,286.19 90,839,459.16 columns)

Add: Non-operating income 35,817.37 1,178,963.53 Less: Non-operating expenses 434,948.21 37,395.28

4. Total profit (total loss is marked with "-"

75,446,155.35 91,981,027.41 fill in the column)

Less: Income tax expense 10,162,097.57 12,209,725.64

5. Net profit (net loss is filled in with "-"

65,284,057.78 79,771,301.77 columns)

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

65,284,057.78 79,771,301.77 (Fill in “-”)

Net profit from discontinued operations (net loss equal to

Fill in the column with "-" sign)

(2) Classification according to ownership ownership

Net profit attributable to owners of the parent company 64,750,179.59 80,420,300.50 2. Profit and loss of minority shareholders 533,878.19 -648,998.73
Net after-tax other comprehensive income 401,378.14 -2,125,749.93 Other comprehensive income attributable to owners of the parent company

401,378.14 -2,125,749.93 net amount after tax

(1) Others that cannot be reclassified into profit or loss

Comprehensive income

Remeasure changes in defined benefit plans

Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

Fair value of other equity instrument investments

change

Fair value of the company’s own credit risk

change

5.Others

(2) Other comprehensive items that will be reclassified into profit or loss

401,378.14 -2,125,749.93 combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive

Amount of combined income

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements 401,378.14 -2,125,749.93 7. Others

Other comprehensive income attributable to minority shareholders

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

net of tax

Total comprehensive income 65,685,435.92 77,645,551.84 Total comprehensive income attributable to owners of the parent company

65,151,557.73 78,294,550.57 amount

Total comprehensive income attributable to minority shareholders 533,878.19 -648,998.73

8. Earnings per share:

(1) Basic earnings per share 0.13 0.17

(2) Diluted earnings per share 0.13 0.17 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan.

Legal representative: Zhang Junzheng Person in charge of accounting work: Liu Aimin Person in charge of accounting department: Li Chunping

Consolidated cash flow statement

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 315,064,887.24 323,103,011.87 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 5,843,345.69 19,134,427.09 Other cash received related to operating activities 12,879,235.99 9,418,458.05 Subtotal of cash inflows from operating activities 333,787,468.92 351,655,897.01 Cash paid for purchasing goods and receiving services 148,814,167.74 183,888,759.92

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 58,700,104.79 54,515,919.28 Various taxes and fees paid 19,823,966.49 37,760,309.01 Cash paid for other operating activities 34,810,795.39 27,976,732.51 Subtotal of cash outflows from operating activities 262,149,034.41 304,141,720.72 Net cash flow generated from operating activities 71,638,434.51 47,514,176.29

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income

Disposal of fixed assets, intangible assets and other long-term

17,274.18

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 290,000,000.00

Boai New Kaiyuan Medical Technology Group Co., Ltd. 2026 First Quarter Report

Subtotal of cash inflows from investing activities 17,274.18 290,000,000.00 Purchase and construction of fixed assets, intangible assets and other long-term assets

91,525,996.50 89,193,480.17 Cash paid for assets

Cash paid for investments

Net increase in mortgage loans

Obtain payment from subsidiaries and other business units

net cash

Other cash payments related to investing activities

Subtotal of cash outflows from investing activities 91,525,996.50 89,193,480.17 Net cash flow generated from investing activities -91,508,722.32 200,806,519.83

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment from minority shareholders

cash received

Cash received from borrowing 5,000,000.00 245,160,000.00

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 5,000,000.00 245,160,000.00 Cash paid to repay debts 6,500,000.00 205,500,000.00 Cash paid to distribute dividends, profits or pay interest

964,041.36 997,499.56 cash

Including: Payments made by subsidiaries to minority shareholders

dividends, profits

Cash payments related to other financing activities 49,979,761.38

Subtotal of cash outflows from financing activities 57,443,802.74 206,497,499.56 Net cash flow generated from financing activities -52,443,802.74 38,662,500.44

4. The impact of exchange rate changes on cash and cash equivalents

-1,546,185.67 1,314,814.94 impact

Net increase in cash and cash equivalents -73,860,276.22 288,298,011.50

Add: Balance of cash and cash equivalents at the beginning of the period 631,428,408.60 479,252,808.01

Balance of cash and cash equivalents at the end of the period 557,568,132.38 767,550,819.51

(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2026